Pathology, Trauma, and Forensic Radiography

Jan 17th, 2014
San Francisco, CA
US
https://store2.aheconline.com/index.php?route=product/product&path=59_81&product_id=1055
This course is designed to improve your overall awareness of the tissue density differences in diseases and trauma cases at various stages.
Latest in Home
Parametric maps obtained with SRTM2 (cerebellum grey matter as reference) for the group of healthy participants (top) and from one representative participant with suspected CTE (bottom). CTE: chronic traumatic encephalopathy.
SNMMI: PET tracer detects CTE tau pathology in living patients
May 31, 2026
Sample images from each participant group: A: CT only; B: fused Tc-99m maraciclatide SPECT/CT.
SNMMI: SPECT/CT tracer shows promise in interstitial lung disease
May 31, 2026
Picture3
SNMMI: Alpha-emitting tracer offers neuroendocrine tumor treatment option
May 31, 2026
Asco Thumb
ASCO: Should pathogenic variants be considered in breast cancer screening?
May 31, 2026
More in Home
SNMMI: PET tracer detects CTE tau pathology in living patients
By Kate Madden Yee
Study findings suggest "a clinical role for PET in traumatic brain injury and sports- and military-related neurodegeneration."
May 31, 2026
Parametric maps obtained with SRTM2 (cerebellum grey matter as reference) for the group of healthy participants (top) and from one representative participant with suspected CTE (bottom). CTE: chronic traumatic encephalopathy.
SNMMI: SPECT/CT tracer shows promise in interstitial lung disease
By Will Morton
Differentiating between fibrotic scarring and inflammation stages of disease is critical so that physicians can determine what treatment is best for the patient.
May 31, 2026
Sample images from each participant group: A: CT only; B: fused Tc-99m maraciclatide SPECT/CT.
SNMMI: Alpha-emitting tracer offers neuroendocrine tumor treatment option
By Kate Madden Yee
An alpha-emitting radiotracer produced remission in patients who had exhausted typical treatment options for neuroendocrine tumors.
May 31, 2026
Picture3
ASCO: Should pathogenic variants be considered in breast cancer screening?
By Erik L. Ridley
Germline testing for PVs identify different subsets of high-risk women in risk-based breast cancer screening strategies.
May 31, 2026
Asco Thumb
SNMMI: PET tracer detects both cardiac Inflammation and tumor activity
By Will Morton
CCR2 is expressed in both atherosclerotic plaques and tumors.
May 31, 2026
Combination therapy of JAK1i with anti-PD1 slows down tumor growth and reduces CCR2+ cells infiltration in atherosclerotic lesions compared to anti-PD1 alone. Representative PET images of cardio-oncology mice treated with anti-PD1 alone or in combination with JAK1i. The PET uptake was normalized by subtracting blood retention.
SNMMI: Prostate cancer vaccines may improve response to Pluvicto
By Will Morton
Immunological priming before radiopharmaceutical therapy may enhance clinical efficacy without impairing prostate antigen-specific T cell response.
May 31, 2026
Snmmi Thumb
ASCO: Lu-177 edotreotide yields sustained quality-of-life gains
By Erik L. Ridley
A poster presentation at ASCO 2026 highlighted quantifiable benefits for patients receiving the radiopharmaceutical treatment for GEP-NETs.
May 31, 2026
Asco Thumb
SNMMI: Jeremie Calais discusses theranostics (and football)
By Will Morton
Jeremie Calais, MD, of the University of California, Los Angeles, discussed the present state of the field of theranostics, as well as it’s future potential.
May 31, 2026
Calais Snmmi
SNMMI: Phillip Kuo discusses Alzheimer’s disease imaging and treatment
By Will Morton
Phillip Kuo, MD, PhD, discussed developments in diagnosing and treating Alzheimer’s disease at the SNMMI meeting.
May 31, 2026
Phillip Kuo
SNMMI: Music relieves anxiety, cuts perceived SPECT/CT scan time
By Kate Madden Yee
Research findings could improve the experience of patients undergoing these exams as well as the quality of the imaging itself.
May 31, 2026
Snmmi Thumb
SNMMI: New brain imaging agent tracks progressive supranuclear palsy
By Kate Madden Yee
The tracer, called [F-18] OXD-2314, successfully identified abnormal proteins in key brain regions of patients with the disease.
May 31, 2026
Snmmi Thumb
SNMMI: Machine-learning model predicts RPT dose
By Will Morton
Dosimetry plays a central role in optimizing lutetium-177 (Lu-177) PSMA therapy, yet calculating it currently depends on post-therapy imaging.
May 30, 2026
Snmmi Thumb
Page 1 of 229
Next Page